Your Messages Inbox (38) 
Your Unread Messages
See All
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Oral anticoagulant therapy safely prevented stroke in older patients with atrial fibrillation
Evidence-Based Medicine, 10/26/09
Dunn A – In patients with atrial fibrillation, the effectiveness of antiplatelet therapy for stroke prevention decreased with age, but that of oral anticoagulants did not. Relative risk of serious bleeding with oral anticoagulants was not affected by age.
Methods- Individual patient data meta–analysis of 12 randomised controlled trials (RCTs). 6 RCTs were placebo–controlled; 8 RCTs compared an oral anticoagulant (OAC) with an antiplatelet (AP).
- Patients: 8932 adults (mean age 72 y, 63% men) with non–valvular atrial fibrillation. Patients with clinical indications for or against any of the active therapies were excluded.
- Interventions: full–dose OACs (mainly warfarin sodium or 4–hydroxycoumarin) with lower target international normalised ratio (INR) of 1.5–2.8 and upper target INR of 2.7–4.2 (n = 3430); APs (mainly acetylsalicylic acid, 75–325 mg) with or without low–dose OACs (median INR <1.5; n = 3531); or placebo (n = 1971).
- Outcomes: ischaemic stroke, serious bleeding, and cardiovascular events (ischaemic stroke, myocardial infarction, systemic embolism, or vascular death). Intention–to–treat analysis.
- Older age was associated with increased risk of all outcomes.
- Independent of age and other covariates, both OACs and APs decreased risk of stroke and cardiovascular events compared with placebo; OACs, but not APs, increased risk of serious bleeding.
- The treatment effect of OACs decreased slightly in older patients: The adjusted hazard ratio for ischaemic stroke with OAC use was 0.22 at age 50 years and 0.53 at age 90 years.
- In contrast, the treatment effect of APs decreased considerably in older patients: The adjusted hazard ratio for ischaemic stroke with AP use was 0.40 at age 50 years, gradually increasing until it exceeded 1 at about age 82 years and reaching 1.25 at age 90 years.
- Age did not influence the effect of treatment with either drug on serious bleeding or cardiovascular events.
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09
Coenzyme Q10; an adjunctive therapy for congestive heart failure?
New Zealand Medical Journal, 11/04/09
Sponsor
Article Search
Sponsor